We are live on ! Find out more
EVMN

Evommune Inc
EVMN

84 hedge funds and large institutions have $793M invested in Evommune Inc in 2026 Q1 according to their latest regulatory filings, with 37 funds opening new positions, 26 increasing their positions, 11 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

270% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 10

136% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 11

70% more capital invested

Capital invested by funds: $466M → $793M (+$328M)

42% more funds holding

Funds holding: 59 → 84 (+25)

9.71% more ownership

Funds ownership: 86.29% → 96% (+9.7%)

0% more funds holding in top 10

Funds holding in top 10: 7 → 7 (0)

Holders
84
Holders Change
+25
Holders Change %
+42.37%
% of All Funds
1.03%
Holding in Top 10
7
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
37
Increased
26
Reduced
11
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
MB
MPM BioImpact
Massachusetts
+$30.4M
2
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$20.3M
3
BBA
Baker Bros. Advisors
New York
+$19.2M
4
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$16.4M
5
BlackRock
BlackRock
New York
+$12M

Top Sellers

Rank Fund Capital Flow
1
Aberdeen Group
Aberdeen Group
United Kingdom
-$8.99M
2
OCA
Octagon Capital Advisors
New York
-$8.06M
3
SI
Sofinnova Investments
California
-$2.62M
4
Marshall Wace
Marshall Wace
United Kingdom
-$2.45M
5
SFM
Sphera Funds Management
Israel
-$1.99M
Name Holding Trade Value Shares
Change 		Change in
Stake
EFM
1
EQT Fund Management
Luxembourg
$113M – – –
RCM
2
RA Capital Management
Massachusetts
$80.3M +$811K +35,868 +1%
PBPIA
3
Pivotal bioVenture Partners Investment Advisor
California
$44.3M – – –
AP
4
Andera Partners
$43.6M – – –
RI
5
RTW Investments
New York
$34.5M +$4.94M +218,564 +17%
MB
6
MPM BioImpact
Massachusetts
$33.5M +$30.4M +1,342,841 +1,188%
NFGH
7
Nan Fung Group Holdings
Hong Kong
$33.1M – – –
JP Morgan Chase
8
JP Morgan Chase
New York
$32.1M +$3.4M +150,519 +11%
SCP
9
SymBiosis Capital Partners
Arkansas
$29.4M – – –
EAM
10
Eventide Asset Management
Massachusetts
$27.8M +$5.6M +247,604 +26%
T. Rowe Price Associates
11
T. Rowe Price Associates
Maryland
$25.7M +$7.62M +336,900 +43%
Janus Henderson Group
12
Janus Henderson Group
United Kingdom
$20.6M +$20.3M +896,700 New
Marshall Wace
13
Marshall Wace
United Kingdom
$20.2M -$2.45M -108,472 -11%
BBA
14
Baker Bros. Advisors
New York
$19.5M +$19.2M +847,390 New
Alyeska Investment Group
15
Alyeska Investment Group
Illinois
$16.7M +$16.4M +726,362 New
DCM
16
Defilade Capital Management
California
$15.6M +$10.5M +463,171 +215%
BlackRock
17
BlackRock
New York
$15.5M +$12M +531,131 +373%
KCM
18
Kynam Capital Management
New Jersey
$14.4M +$9.95M +440,014 +237%
SAM
19
Sectoral Asset Management
Quebec, Canada
$13.5M – – –
Verition Fund Management
20
Verition Fund Management
Connecticut
$12.6M -$344K -15,223 -3%
American Century Companies
21
American Century Companies
Missouri
$11.3M +$1.71M +75,483 +18%
VCM
22
Vanguard Capital Management
Pennsylvania
$10.5M +$10.3M +455,051 New
PA
23
Perceptive Advisors
New York
$10.3M +$10.1M +448,350 New
VCIM
24
Velan Capital Investment Management
Georgia
$10.3M -$1.37M -60,499 -12%
FGP
25
Freestone Grove Partners
California
$7.75M +$7.63M +337,291 New
1
2 3 4

EVMN Hedge Fund Activity: Q1 2026 in Review

84 of the 8,129 institutional investors tracked by Wall St. Rank reported a position in Evommune Inc (EVMN) for Q1 2026, worth a combined $793M — up 70% from $466M a quarter earlier.

Buyers outnumbered sellers: 37 funds opened new EVMN positions and 10 closed out — a net gain of 27 holders — while 26 added to existing stakes and 11 trimmed.

The largest buyer was MPM BioImpact, adding an estimated $30.4M. The largest seller was Aberdeen Group, exiting entirely with an estimated $8.99M sold.

  • 84 institutional investors held Evommune Inc (EVMN) as of Q1 2026, up from 59 in Q4 2025.
  • Funds reported $793M of Evommune Inc stock for Q1 2026, up 70% quarter-over-quarter.
  • 37 funds opened new Evommune Inc positions in Q1 2026 and 10 closed out, a net change of +27 holders.
  • The largest Evommune Inc buyer in Q1 2026 was MPM BioImpact, an estimated $30.4M added.
  • The largest Evommune Inc seller in Q1 2026 was Aberdeen Group, an estimated $8.99M sold.

Based on aggregated 13F filings for Q1 2026.